Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method for Entos Pharmaceuticals that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.
Cytiva, formerly part of GE Healthcare Life Sciences, will work with Entos Pharmaceuticals to optimize a clinical manufacturing solution for the company’s Covigenix COVID-19 DNA vaccine candidate. Entos Pharmaceuticals develops next generation nucleic acid medicines using their Fusogenix platform, which uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells.
Cytiva’s Fast Trak process development team will develop efficient and scalable processes to manufacture the Fusogenix technology platform. Anne-Cécile Potmans, General Manager, Fast Trak, Cytiva says, “Advancing vaccine candidates requires innovation, speed and collaboration. When emerging biotechnology companies like Entos engage with our teams, they are able to collaborate with industry specialists to accelerate the development of transformative medicines.”
Dr. John Lewis, CEO, Entos Pharmaceuticals, says, “Cytiva has a winning combination of deep expertise and a stellar track record in manufacturing process optimization. As we look forward to advancing our pan-coronavirus COVID-19 vaccine, it is essential that our manufacturing strategy can be scaled effectively and safely to address the urgent global need.”
Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery. By collaborating with Cytiva, Entos will have a robust purification process that will enable them to manufacture multiple vaccine candidates and begin human clinical trials.
With more than 300 years of collective industrial knowledge, the Fast Trak team helps biotech companies around the world to develop and optimize their upstream and downstream processes.
Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 employees across 40 sites dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.